Toward a carbohydrate-based HIV-1 vaccine: Synthesis and immunological studies of oligomannose-containing glycoconjugates

被引:98
作者
Ni, JH [1 ]
Song, HJ [1 ]
Wang, YD [1 ]
Stamatos, NM [1 ]
Wang, LX [1 ]
机构
[1] Univ Maryland, Inst Biotechnol, Inst Human Virol, Baltimore, MD 21201 USA
关键词
D O I
10.1021/bc0502816
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Human antibody 2G12 is a broadly neutralizing antibody that exerts its anti-HIV activity by targeting a novel oligomannose cluster on HIV-1 gp120. It was previously demonstrated that synthetic oligomannose clusters could mimic the carbohydrate epitope of 2G12 and showed enhanced antigenicity (Wang L. X. et al. (2004) Chem. Biol. 11, 127). This paper describes the synthesis of oligomannose-containing glycoconjugates that include either a carrier protein or a universal T-helper epitope peptide to provide an effective immunogen. It was shown that the synthetic neoglycoconjugates containing oligomannose clusters could be recognized by the human antibody 2G12. Rabbit immunization studies revealed that only a small fraction of antibodies raised by the glycoconjugates was directed to the carbohydrate antigens, with the majority of the IgG type antibodies being directed to the linkers in the conjugates. The anti-sera showed weak cross-reactivity to HIV-1 gp120.
引用
收藏
页码:493 / 500
页数:8
相关论文
共 39 条
  • [1] Oligosaccharide and glycoprotein Microarrays as tools in HIV glycobiology: Glycan-dependent gp120/protein interactions
    Adams, EW
    Ratner, DM
    Bokesch, HR
    McMahon, JB
    O'Keefe, BR
    Seeberger, PH
    [J]. CHEMISTRY & BIOLOGY, 2004, 11 (06): : 875 - 881
  • [2] A phase I trial with two human monoclonal antibodies (hMAb 2F5, 2G12) against HIV-1
    Armbruster, C
    Stiegler, GM
    Vcelar, BA
    Jäger, W
    Michael, NL
    Vetter, N
    Katinger, HWD
    [J]. AIDS, 2002, 16 (02) : 227 - 233
  • [3] Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection
    Baba, TW
    Liska, V
    Hofmann-Lehmann, R
    Vlasak, J
    Xu, WD
    Ayehunie, S
    Cavacini, LA
    Posner, MR
    Katinger, H
    Stiegler, G
    Bernacky, BJ
    Rizvi, TA
    Schmidt, R
    Hill, LR
    Keeling, ME
    Lu, YC
    Wright, JE
    Chou, TC
    Ruprecht, RM
    [J]. NATURE MEDICINE, 2000, 6 (02) : 200 - 206
  • [4] HIV vaccine design and the neutralizing antibody problem
    Burton, DR
    Desrosiers, RC
    Doms, RW
    Koff, WC
    Kwong, PD
    Moore, JP
    Nabel, GJ
    Sodroski, J
    Wilson, IA
    Wyatt, RT
    [J]. NATURE IMMUNOLOGY, 2004, 5 (03) : 233 - 236
  • [5] The immunogenicity of the tumor-associated antigen Lewisy may be suppressed by a bifunctional cross-linker required for coupling to a carrier protein
    Buskas, T
    Li, YH
    Boons, GJ
    [J]. CHEMISTRY-A EUROPEAN JOURNAL, 2004, 10 (14) : 3517 - 3524
  • [6] Antibody domain exchange is an immunological solution to carbohydrate cluster recognition
    Calarese, DA
    Scanlan, CN
    Zwick, MB
    Deechongkit, S
    Mimura, Y
    Kunert, R
    Zhu, P
    Wormald, MR
    Stanfield, RL
    Roux, KH
    Kelly, JW
    Rudd, PM
    Dwek, RA
    Katinger, H
    Burton, DR
    Wilson, IA
    [J]. SCIENCE, 2003, 300 (5628) : 2065 - 2071
  • [7] Dissection of the carbohydrate specificity of the broadly neutralizing-anti-HIV-1 antibody 2G12
    Calarese, DA
    Lee, HK
    Huang, CY
    Best, MD
    Astronomo, RD
    Stanfield, RL
    Katinger, H
    Burton, DR
    Wong, CH
    Wilson, IA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (38) : 13372 - 13377
  • [8] Calarota Sandra A, 2003, AIDS, V17 Suppl 4, pS73, DOI 10.1097/00002030-200317004-00009
  • [9] Danishefsky SJ, 2000, ANGEW CHEM INT EDIT, V39, P836, DOI 10.1002/(SICI)1521-3773(20000303)39:5<836::AID-ANIE836>3.0.CO
  • [10] 2-I